{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T14:28:23Z","timestamp":1772029703548,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,14]]},"DOI":"10.7759\/cureus.69401","type":"journal-article","created":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T12:40:58Z","timestamp":1726317658000},"source":"Crossref","is-referenced-by-count":1,"title":["Fexofenadine As Successful Adjunctive Treatment of Rheumatoid Arthritis and Trochanteric Bursitis: A Case Report"],"prefix":"10.7759","author":[{"given":"Ellen","family":"Yos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Hines","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Therese","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine M","family":"Angeles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A","family":"Chetrit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/cells10112857","article-title":"Management of rheumatoid arthritis: an overview","volume":"10","author":"Radu AF","year":"2021","unstructured":"Radu AF, Bungau SG. Management of rheumatoid arthritis: an overview. Cells. 2021, 10:2857. 10.3390\/cells10112857","journal-title":"Cells"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06075-5","article-title":"Rheumatoid arthritis","volume":"358","author":"Lee DM","year":"2001","unstructured":"Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet. 2001, 358:903-11. 10.1016\/S0140-6736(01)06075-5","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/art.42089","article-title":"Prevalence trends of site-specific osteoarthritis from 1990 to 2019: Findings from the global burden of disease study 2019","volume":"74","author":"Long H","year":"2022","unstructured":"Long H, Liu Q, Yin H, et al.. Prevalence trends of site-specific osteoarthritis from 1990 to 2019: Findings from the global burden of disease study 2019. Arthritis Rheumatol. 2022, 74:1172-83. 10.1002\/art.42089","journal-title":"Arthritis Rheumatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2017.08.003","article-title":"Genetic and environmental risk factors for rheumatoid arthritis","volume":"31","author":"Deane KD","year":"2017","unstructured":"Deane KD, Demoruelle MK, Kelmenson LB, Kuhn KA, Norris JM, Holers VM. Genetic and environmental risk factors for rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2017, 31:3-18. 10.1016\/j.berh.2017.08.003","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"ref5","article-title":"Trochanteric Bursitis (Archived)","author":"Seidman AJ","year":"2024","unstructured":"Seidman AJ, Taqi M, Varacallo M. Trochanteric Bursitis (Archived). StatPearls Publishing, Treasure Island, FL; 2024."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/ard.41.6.602","article-title":"Trochanteric bursitis--a frequent cause of 'hip' pain in rheumatoid arthritis","volume":"41","author":"Raman D","year":"1982","unstructured":"Raman D, Haslock I. Trochanteric bursitis--a frequent cause of 'hip' pain in rheumatoid arthritis. Ann Rheum Dis. 1982, 41:602-3. 10.1136\/ard.41.6.602","journal-title":"Ann Rheum Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/870145","article-title":"Relationship between bone mineral density and the frequent administration of epidural steroid injections in postmenopausal women with low back pain","volume":"19","author":"Kim S","year":"2014","unstructured":"Kim S, Hwang B. Relationship between bone mineral density and the frequent administration of epidural steroid injections in postmenopausal women with low back pain. Pain Res Manag. 2014, 19:30-4. 10.1155\/2014\/870145","journal-title":"Pain Res Manag"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-012-0275-1","article-title":"Treatment strategies in early rheumatoid arthritis and prevention of rheumatoid arthritis","volume":"14","author":"Demoruelle MK","year":"2012","unstructured":"Demoruelle MK, Deane KD. Treatment strategies in early rheumatoid arthritis and prevention of rheumatoid arthritis. Curr Rheumatol Rep. 2012, 14:472-80. 10.1007\/s11926-012-0275-1","journal-title":"Curr Rheumatol Rep"},{"key":"ref9","article-title":"","author":"Benjamin O","year":"2024","unstructured":"Benjamin O, Goyal A, Lappin SL. Disease-Modifying Antirheumatic Drugs (DMARD). StatPearls Publishing, Treasure Island, FL; 2024. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK507863\/."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes283","article-title":"Overview of safety of non-biologic and biologic DMARDs","volume":"51 Suppl 6","author":"Ruderman EM","year":"2012","unstructured":"Ruderman EM. Overview of safety of non-biologic and biologic DMARDs. Rheumatology (Oxford). 2012, 51 Suppl 6:vi37-43. 10.1093\/rheumatology\/kes283","journal-title":"Rheumatology (Oxford)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.4176\/070314","article-title":"Central nervous system demyelination associated with etanercept in a 51 years old woman","volume":"2","author":"Ibrahim WH","year":"2007","unstructured":"Ibrahim WH, Hammoudah M, Akhtar N, Al-Hail H, Deleu D. Central nervous system demyelination associated with etanercept in a 51 years old woman. Libyan J Med. 2007, 2:99-102. 10.4176\/070314","journal-title":"Libyan J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200112)44:12%3C2862::aid-art474%3E3.0.co;2-w","article-title":"Demyelination occurring during anti-tumor necrosis factor \u03b1 therapy for inflammatory arthritides","volume":"44","author":"Mohan N","year":"2001","unstructured":"Mohan N, Edwards ET, Cupps TR, et al.. Demyelination occurring during anti-tumor necrosis factor \u03b1 therapy for inflammatory arthritides. Arthritis Rheumat. 2001, 44:12-2862. 10.1002\/1529-0131(200112)44:12%3C2862::aid-art474%3E3.0.co;2-w","journal-title":"Arthritis Rheumat"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215543","article-title":"Fexofenadine inhibits TNF signaling through targeting to cytosolic phospholipase A2 and is therapeutic against inflammatory arthritis","volume":"78","author":"Liu R","year":"2019","unstructured":"Liu R, Chen Y, Fu W, et al.. Fexofenadine inhibits TNF signaling through targeting to cytosolic phospholipase A2 and is therapeutic against inflammatory arthritis. Ann Rheum Dis. 2019, 78:1524-35. 10.1136\/annrheumdis-2019-215543","journal-title":"Ann Rheum Dis"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/nature12332","article-title":"Non-vesicular trafficking by a ceramide-1-phosphate transfer protein regulates eicosanoids","volume":"500","author":"Simanshu DK","year":"2013","unstructured":"Simanshu DK, Kamlekar RK, Wijesinghe DS, et al.. Non-vesicular trafficking by a ceramide-1-phosphate transfer protein regulates eicosanoids. Nature. 2013, 500:463-7. 10.1038\/nature12332","journal-title":"Nature"},{"key":"ref15","unstructured":"Fexofenadine capsules or tablets. (2024). Accessed. August 30, 2024: https:\/\/my.clevelandclinic.org\/health\/drugs\/20104-fexofenadine-capsules-or-tablets."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2015.21.4.318","article-title":"Cost and effectiveness of biologics for rheumatoid arthritis in a commercially insured population","volume":"21","author":"Curtis JR","year":"2015","unstructured":"Curtis JR, Chastek B, Becker L, et al.. Cost and effectiveness of biologics for rheumatoid arthritis in a commercially insured population. J Manag Care Spec Pharm. 2015, 21:318-29. 10.18553\/jmcp.2015.21.4.318","journal-title":"J Manag Care Spec Pharm"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/cells9040880","article-title":"Update on the pathomechanism, diagnosis, and treatment options for rheumatoid arthritis","volume":"9","author":"Lin YJ","year":"2020","unstructured":"Lin YJ, Anzaghe M, Sch\u00fclke S. Update on the pathomechanism, diagnosis, and treatment options for rheumatoid arthritis. Cells. 2020, 9:880. 10.3390\/cells9040880","journal-title":"Cells"},{"key":"ref18","article-title":"Diagnosis and management of rheumatoid arthritis","volume":"84","author":"Wasserman AM","year":"2011","unstructured":"Wasserman AM. Diagnosis and management of rheumatoid arthritis. Am Fam Physician. 2011, 84:1245-52.","journal-title":"Am Fam Physician"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.113949","article-title":"Loratadine, an antihistamine drug, exhibits anti-inflammatory activity through suppression of the NF-(k)B pathway","volume":"177","author":"Hunto ST","year":"2020","unstructured":"Hunto ST, Kim HG, Baek KS, Jeong D, Kim E, Kim JH, Cho JY. Loratadine, an antihistamine drug, exhibits anti-inflammatory activity through suppression of the NF-(k)B pathway. Biochem Pharmacol. 2020, 177:113949. 10.1016\/j.bcp.2020.113949","journal-title":"Biochem Pharmacol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2008.02963.x","article-title":"Montelukast inhibits tumour necrosis factor-alpha-mediated interleukin-8 expression through inhibition of nuclear factor-kappaB p65-associated histone acetyltransferase activity","volume":"38","author":"Tahan F","year":"2008","unstructured":"Tahan F, Jazrawi E, Moodley T, Rovati GE, Adcock IM. Montelukast inhibits tumour necrosis factor-alpha-mediated interleukin-8 expression through inhibition of nuclear factor-kappaB p65-associated histone acetyltransferase activity. Clin Exp Allergy. 2008, 38:805-11. 10.1111\/j.1365-2222.2008.02963.x","journal-title":"Clin Exp Allergy"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/272157-fexofenadine-as-successful-adjunctive-treatment-of-rheumatoid-arthritis-and-trochanteric-bursitis-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T12:41:03Z","timestamp":1726317663000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/272157-fexofenadine-as-successful-adjunctive-treatment-of-rheumatoid-arthritis-and-trochanteric-bursitis-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,14]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.69401","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,14]]}}}